KDR and cancer: Although considered a breakthrough for cancer treatment, current VEGFR2 therapy is facing major drawbacks in terms of efficiency, as well as the rapid development of resistance through secondary mutation, upregulation of angiogenic pathways, hypoxia-driven metastasis, vascular co-optation, mimicry, or the involvement of cancer stem cells [16,17,18].